Navigation Links
Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
Date:11/14/2011

a strongly support further development of Virobay's spectrum-selective cathepsin inhibitors in metastatic and primary bone cancer, and that this novel therapeutic approach may be especially valuable in combination with existing anticancer approaches."

VBY-825 is a member of a series of highly potent, spectrum-selective cathepsin inhibitors with structural diversity, which is being developed by Virobay.  Increased cathepsin levels and activity have been shown to play a role in a variety of tumors, including lung and breast, and are correlated to poor patient prognosis.  The proteolytic activity of multiple cathepsins may play a role in degradation of the basement membrane and extracellular matrix allowing a loss of cell adhesion and facilitating tumor metastasis.  Cathepsin K inhibition has been shown to suppress bone resorption in women with post-menopausal osteoporosis as well as women with breast cancer by inhibiting osteoclast function.  Studies with cathepsin S inhibitors have demonstrated a reduction in the perception of pain (nociception) in animals, with no sedating effects, suggesting a role for cathepsin S in neuropathic and inflammatory pain.

About Virobay

Virobay is a leader in the design, synthesis and development of small molecule inhibitors of cysteine proteases, a diverse class of enzyme proteases that are key mediators in a variety of diseases, including autoimmunity, neuropathic pain, liver disease, cancer, and cardiovascular disorders.  Virobay was founded upon a rich industry legacy of intensive research and development focused on the cathepsin family of cysteine proteases.  Today, Virobay possesses a trove of maturing assets, including an advancing clinical pipeline and well-characterized libraries of highly potent and selective inhibitors with drug-like pharmacokinetics consistent with the potential for oral once-daily dosing in humans.

Virobay's unique expertise in the structure
'/>"/>

SOURCE Virobay, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
2. Study Shows C1-Esterase Inhibitor Concentrate is Safe and Consistently Effective for Long-Term Treatment of Hereditary Angioedema Attacks at Any Body Location
3. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
4. ViiV Healthcare Starts Phase III Clinical Programme of Celsentri/Selzentry® (maraviroc) versus Truvada® (tenofovir + FTC), in combination with a Protease Inhibitor in people living with HIV
5. Enantas Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhovers Top 10 Infectious Disease Projects to Watch
6. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
7. Modulation of inhibitory output is key function of antiobesity hormone
8. Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor
9. Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
10. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
11. Pharmacyclics Achieves $7 Million Development Milestone for HDAC Inhibitor, PCI-24781 / S 78454 with Servier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Research and Markets has announced the addition ... Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - ... The global molecular biology enzymes market was ... to grow at a CAGR of 13.74% to reach ... reagents find applications in a large number of fields ...
(Date:8/22/2014)... 22, 2014 “Our nation's healthcare ... a national disgrace. Furthermore, every governmental and professional ... current, deplorable state of unorganized dysfunction shares in ... to merely serve as a device to use ... colossal failure(s) that have accumulated through the years ...
(Date:8/21/2014)... including DESY scientists has observed tiny quantum vortices in ... the journal Science that the exotic vortices ... It is the first time that the quantum vortices, ... what is known as superfluid helium, have been detected ... says Andrey Vilesov of the University of Southern California, ...
(Date:8/21/2014)... , Aug. 21, 2014 Telomere ... of their Nutraceutical "TELO-20 for Dogs" with ... Telomere-lengthening supplement in the world for dogs. Telomeres ... every chromosome in the body. A wealth of ... experts in Telomere Science and Aging, including Nobel ...
Breaking Biology Technology:Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 2Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 35 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2Scientists observe quantum vortices in cold helium droplets 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3
... adds advanced cholesterol testing capabilities, BIRMINGHAM, ... company, today announced that its VAP(R) Cholesterol ... released health,assessment, BiophysicalCheck., The announcement means ... ability to,identify far more areas of risk ...
... (Nasdaq: BCRX ) today announced that its ... Thursday, August 7, 2008. Following,the release, BioCryst will ... a.m.,Eastern Time to discuss the financial results and ... will be led by Jon P. Stonehouse, BioCryst,s,Chief ...
... 31 NeoStem, Inc. (Amex: NBS ),has announced ... cell,collection centers. Through a development agreement with Stem Collect ... Monica based medical,practice., The Los Angeles area is ... a large concentration of physician practices,and hospitals offering a ...
Cached Biology Technology:VAP(R) Cholesterol Test Bolsters Biophysical(R) Health Assessment 2VAP(R) Cholesterol Test Bolsters Biophysical(R) Health Assessment 3BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008 2BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008 3NeoStem Expands Adult Stem Cell Collection Network, Gains Footprint in Key Los Angeles Market and Initiates Waitlist 2NeoStem Expands Adult Stem Cell Collection Network, Gains Footprint in Key Los Angeles Market and Initiates Waitlist 3
(Date:8/21/2014)... A new study of American singles found that ... the highest orgasm rates. On average, men experience ... sexual orientation making little difference. For women, however, ... experience orgasm 62.9 percent of the time during ... pattern varies with women,s sexual orientation, with lesbian ...
(Date:8/21/2014)... they are the ultimate source of all organic matter ... on algae, too, to suck up climate-warming carbon dioxide ... of the ocean. Now, by using a combination of ... that viruses infecting those algae are driving the life-and-death ... stays essentially the same, and this has important implications ...
(Date:8/21/2014)... A landmark study aimed at improving the food intake, ... long-term care homes is among three projects at the ... grants from the Canadian Institutes of Health Research (CIHR). ... Applied Health Sciences at Waterloo, and a Schlegel research ... two years to investigate why many Canadians living in ...
Breaking Biology News(10 mins):Orgasm rates for single women less predictable than men's, vary by sexual orientation 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 4Viruses take down massive algal blooms, with big implications for climate 2Grants will fund landmark aging research at Waterloo 2
... synthesising chemicals from plant material could produce liquid fuel for ... if the infrastructure is set up in the right way, ... Biofuels, Bioproducts & Biorefining . Developed by scientists at ... known as bioliq, and is able to produce a range ...
... strains of methicillin-resistant Staphylococcus aureus , commonly known ... exposing them to a wavelength of blue light, in ... paper published online ahead of print in Photomedicine ... the April 2009 issue (Volume 27, Number 2) of ...
... some allergic reactions progress quickly and may even become ... 2009 issue of the Journal of Leukocyte Biology ... the answer. In the report, scientists from Queen,s University ... show for the first time that eotaxin, a chemical ...
Cached Biology News:Novel technology could produce biofuel for around 0.50 a liter ($2.49 a gallon) 2Blue light destroys antibiotic-resistant staph infection 2New discovery may lead to new class of allergy drugs 2
Monoclonal Anti-Gα o purified immunoglobulin buffered aqueous solution Solution in phosphate buffered saline pH 7.4, containing 0.08% sodium azide. partially purified bovine brain Gα O ...
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
... 9-Octadecenoyl-N-hydroxylamide Oleoyl-N-hydroxylamide White solid. PROTECT ... potent inhibitor of MMP-2 that acts in ... 1.7 μM). Purity: ≥98% by TLC. ... in solution, reconstitute just prior to use. ...
MAb to Vasopressin Preservative: NaN3...
Biology Products: